Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- A brief history of RNA interference (RNAi)
- Increased activity of the CS enzyme
- Landmark paper
- Timeline of important RNAi discoveries
- Biochemical pathways of Dicer and RISC
- Dicer substrate hypothesis
- Design of dsRNA and nomenclature used in study
- Longer duplexes can be more potent
- Map of EGFP target sites
- Improved potency at EGFP site-2 and site-3
- Targeting endogenous genes hnRNPH and La
- Dose response curves for EGFP-S1
- Experiments "in vitro" with various dsRNAs
- 27mer is cleaved "in vivo" to 21 mer size
- Results of dicing EGFP-S1 27+0 "in vitro"
- Tiling experiment
- 27mers can have longer duration of silencing (1)
- 27mers can have longer duration of silencing (2)
- 27mers do not trigger IFN or PKR responses
- 27mer Dicer-substrate dsRNAs as triggers of RNAi
- Example: suppression of STAT1 gene
- Not all 27mers work well - STAT-1 data
- 27mers work better at a TNF-alfa target site
- 27mers work better at a Stratifin target site
- Why do some 27mers work better than others?
- Effect of end modification on dicing
- Understanding dicing patterns
- EGFP-S3 blunt 27mer dicing pattern
- The variety of blunt 27mers dicing patterns
- SAR - structure activity relationship study (1)
- Summary of SAR ESI - dicing studies
- Mass Spec dicing results for EGFP-S1 L-form
- Mass Spec dicing results for EGFP-S1 R-form
- Two different 27mers can produce the same 21mer
- R 27mer is more potent than L 27mer at EGFP-S1
- R 27mer is more potent than L 27mer at EGFP-S2
- R-form more potent for two sites of hnRNPH
- R-form more potent for TNF
- Effect of dicing on 27mer functional asymmetry
- Prior work that may explain R vs. L potency
- Influence of 27mer asymmetry on RISC loading
- R-form favors "AS" strand loading into RISC
- SAR - structure activity relationship study (2)
- The potency of duplexes >30 bp
- RNA is better than DNA in 3'-overhang
- 3'-overhang length does not matter
- Analysis of all possible 3'-overhang sequences
- Central mutations disrupt function
- Test of the potency of the new 27 mer duplexes
- Results of testing the new 27 mer duplexes
- Can new 27 mer designs be used "in vivo"?
- Suppression of galectin-1 by 27mer dsRNA
- Summary
- Credits
- Other collaborating scientists in the project
- Dicer substrate RNAi publications
- References (1)
- References (2)
- References ( 3)
Topics Covered
- Potency of RNA duplexes of ~27 nucleotides in length
- Dicer substrates
- Variation in dicing patterns
- Defined substrate preferences for Dicer
- Design of RNA duplexes that are processed to specific, desired products
- Dicer processing introduces functional asymmetry into the potency of a RNA duplex
- Preferential binding of Dicer to 3'-overhand
- The exploitation of Dicer properties to improve design of RNAi reagents
Talk Citation
Behlke, M. (2007, October 1). New designs for siRNAs as Dicer substrate [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/HZNH6539.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mark Behlke has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.